Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CUE 
Cue Biopharma (CUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/06/2025: CUE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.88% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.39M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 147142 | Beta 1.42 | 52 Weeks Range 0.45 - 1.99 | Updated Date 06/19/2025 |
52 Weeks Range 0.45 - 1.99 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Earnings Date
Report Date 2025-06-05 | When Before Market | Estimate -0.28 | Actual -0.1279 |
Profitability
Profit Margin - | Operating Margin (TTM) -2921.38% |
Management Effectiveness
Return on Assets (TTM) -67.62% | Return on Equity (TTM) -221.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 43380846 | Price to Sales(TTM) 6.18 |
Enterprise Value 43380846 | Price to Sales(TTM) 6.18 | ||
Enterprise Value to Revenue 5.43 | Enterprise Value to EBITDA -1.76 | Shares Outstanding 75349904 | Shares Floating 75083896 |
Shares Outstanding 75349904 | Shares Floating 75083896 | ||
Percent Insiders 0.35 | Percent Institutions 15.19 |
Analyst Ratings
Rating 4.5 | Target Price 3.5 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cue Biopharma
Company Overview
History and Background
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company founded in 2011. It focuses on developing a novel class of injectable biologics, CUE Biologicsu2122, to selectively engage and modulate the human immune system directly at the disease site to fight cancer, chronic infectious disease, and autoimmune disease.
Core Business Areas
- Immuno-Oncology: Developing CUE Biologicsu2122 to target and activate tumor-specific T cells to eliminate cancer cells. Focuses on solid tumors and hematological malignancies.
- Autoimmune Diseases: Developing CUE Biologicsu2122 to modulate immune responses and reduce inflammation in autoimmune disorders.
Leadership and Structure
The leadership team includes Ayub K. Ommaya, President and CEO. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- CUE-101: CUE-101 is the lead clinical candidate, an IL-2 based E-selectin-binding CUE Biologicu2122, targeting HPV16-driven cancers. Currently in Phase 1b/2 trial. Market share is currently 0 as the product is not yet approved. Competitors include companies developing HPV-targeting therapies and immunotherapies, such as Merck (Keytruda), Bristol Myers Squibb, and Roche.
- CUE-102: CUE-102 is an IL-2 based E-selectin-binding CUE Biologicu2122 designed to target tumors expressing Wilms' Tumor 1 (WT1) protein. Preclinical stage. Market share is currently 0 as the product is not yet approved. Competitors include companies developing WT1-targeting therapies such as SELLAS Life Sciences Group, Inc.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investment in cancer immunotherapy and autoimmune disease treatments.
Positioning
Cue Biopharma is positioned as an innovator in T cell redirection, offering a targeted approach to immunotherapy with its CUE Biologicsu2122 platform.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is estimated to be in the tens of billions of dollars. The TAM for autoimmune disease treatment is also significant. Cue Biopharma is attempting to capture a segment of this TAM through its targeted T-cell modulation approach.
Upturn SWOT Analysis
Strengths
- Novel CUE Biologicsu2122 platform technology
- Targeted approach to immunotherapy
- Strong intellectual property position
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
- Early stage of development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of CUE Biologicsu2122 platform to new indications
- Positive clinical trial results
- Increasing demand for targeted immunotherapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy approaches
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
- SLS
Competitive Landscape
Cue Biopharma differentiates itself through its novel CUE Biologicsu2122 platform. However, it faces intense competition from larger pharmaceutical companies with established immunotherapy products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is based on the development and clinical advancement of its CUE Biologicsu2122 platform.
Future Projections: Future growth depends on the success of clinical trials and potential partnerships. Analyst estimates vary based on the perceived probability of success.
Recent Initiatives: Focus on advancing CUE-101 through clinical trials and expanding the CUE Biologicsu2122 pipeline.
Summary
Cue Biopharma is a development-stage biopharmaceutical company with a novel platform. Clinical trial success is critical for future growth. The company faces significant competition from larger players. Partnerships could strengthen their position, but failure to progress in clinical trials will impact its outlook.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be entirely accurate or complete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cue Biopharma
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2018-01-02 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.cuebiopharma.com |
Full time employees 41 | Website https://www.cuebiopharma.com | ||
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.